NBTX

Nanobiotix SA Sponsored ADR · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website nanobiotix.com
Employees(FY) 101
ISIN US63009J1079

Performance

-5.49%

-17.99%

-41.73%

-31.72%

-57.42%

YTD

-53.31%

Profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Advanced Technical Analysis

Technical Analysis of NBTX 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NBTX

Stock Rank

Recent News & Updates

2024-12-17 03:15
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024(Globenewswire)
2024-12-11 03:15
Voting Rights and Shares Capital of the Company(Globenewswire)
2024-12-09 03:15
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer(Globenewswire)
2024-11-13 03:15
Voting Rights and Shares Capital of the Company(Globenewswire)
2024-11-11 13:30
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms(Globenewswire)
2024-10-30 15:30
NANOBIOTIX to Participate in Multiple Investor Conferences in November(Globenewswire)
2024-10-11 04:15
Voting Rights and Shares Capital of the Company(Globenewswire)
2024-09-18 04:15
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results(Globenewswire)
2024-09-04 04:15
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth(Globenewswire)
2024-09-03 04:15
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-08 04:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2024-07-09 04:15
Voting Rights and Shares Capital of the Company(Globenewswire)
2024-06-12 04:15
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024(Globenewswire)
2024-06-11 04:15
Voting Rights and Shares Capital of the Company(Globenewswire)
2024-06-01 22:00
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Na ve or Resistant to Prior anti-PD-1 Therapy(Globenewswire)
2024-05-28 04:15
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call(Globenewswire)
2024-05-23 04:15
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-21 14:00
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update(Globenewswire)
2024-05-21 04:15
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth(Globenewswire)
2024-05-16 04:15
Voting Rights and Shares Capital of the Company(Globenewswire)
2024-05-15 04:15
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024(Globenewswire)
2024-05-14 04:15
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer(Globenewswire)
2024-04-24 04:40
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results(Globenewswire)
2024-04-17 04:15
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024(Globenewswire)
2024-04-12 22:02
11 Best Nanotechnology Stocks To Invest In(Insidermonkey)
2024-04-10 04:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2024-04-02 04:15
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation(Yahoo Finance)
2024-03-06 03:15
Nanobiotix to Present at Upcoming Investor Conferences in March(Globenewswire)
2024-02-13 03:15
Voting Rights and Shares Capital of the Company(Yahoo Finance)
2024-01-31 03:15
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.